Drugs that contain Ivosidenib
1. List of Tibsovo drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US9850277 | SERVIER | Therapeutically active compositions and their methods of use |
Jan, 2033
(9 years from now) | |
| US9474779 | SERVIER | Therapeutically active compositions and their methods of use |
Aug, 2033
(10 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10610125 | SERVIER | Methods and compositions for cell-proliferation-related disorders |
Jun, 2030
(7 years from now) | |
| US10717764 | SERVIER | Therapeutically active compounds and their methods of use |
Jan, 2033
(9 years from now) | |
| US10799490 | SERVIER | Pharmaceutical compositions of therapeutically active compounds |
Mar, 2035
(12 years from now) | |
| US10449184 | SERVIER | Pharmaceutical compositions of therapeutically active compounds |
Mar, 2035
(12 years from now) | |
| US9968595 | SERVIER | Pharmaceutical compositions of therapeutically active compounds |
Mar, 2035
(12 years from now) | |
| US10653710 | SERVIER | Combination therapy for treating malignancies |
Oct, 2036
(13 years from now) | |
| US10980788 | SERVIER | Therapy for treating malignancies |
Jun, 2039
(16 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 20, 2023 |
| Orphan Drug Exclusivity (ODE) | Aug 25, 2028 |
| New Indication (I) | May 25, 2025 |
NCE-1 date: July, 2022
Market Authorisation Date: 20 July, 2018
Treatment: A method of treating a cancer characterized by an idh1 mutation where the cancer is relapsed or refractory acute myeloid leukemia (aml) and where the mutant idh1 has the ability to convert alpha-ketoglutarate into 2-hydroxyglutarate (2-hg); A method of treating a cancer characterized by an idh1 mutation where the cancer is newly diagnosed acute myeloid leukemia (aml) and where the mutant idh1 has the ability to convert alpha-ketoglutarate into 2-hydroxyglutarate (2-hg); A method of treating previously treated, locally advanced or metastatic cholangiocarcinoma characterized by an idh1 mutation; A method of treating acute myelogenous leukemia (aml) in a subject by administering a pharmaceutical composition where the aml is characterized by the presence of a mutant allele of idh1 and the aml is newly diagnosed; A method of treating acute myelogenous leukemia (aml) in a subject by administering a pharmaceutical composition where the aml is characterized by the presence of a mutant allele of idh1 and where the aml is relapsed/refractory; A method of treating a cancer characterized by an idh1 mutation where the cancer is newly diagnosed acute myeloid leukemia (aml); A method of treating a cancer characterized by an idh1 mutation where the cancer is relapsed or refractory acute myeloid leukemia (aml); Treatment of acute myeloid leukemia (aml) with an idh1 mutation; A method for treating newly diagnosed aml characterized by the presence of a mutant allele of idh1 selected from r132h, r132c, r132l, r132v, r132s and r132gf by administering ivosidenib and azacitidine; A method of treating previously treated, locally advanced or metastatic cholangiocarcinoma characterized by the presence of a mutant allele of idh1 by administering a once daily 500 mg oral dose to a subject that has not ingested a high-fat meal; Treating newly diagnosed acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of idh1 by administering a once daily 500 mg oral dose to a subject that has not ingested a high-fat meal; Treating relapsed/refractory acute myelogenous leukemia (aml) characterized by the presence of a mutant allele of idh1 by administering a once daily 500 mg oral dose to a subject that has not ingested a high-fat meal; A method of treating a cancer characterized by an idh1 mutation where the cancer is acute myelogenous leukemia (aml); A method of treating a cancer characterized by an idh1 mutation wherein the cancer is previously treated, locally advanced or metastatic cholangiocarcinoma
Dosage: TABLET;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic